Conflict of interest
These results were presented in part at the International Symposium of Pediatric Neuro-Oncology (ISPNO) held in June 2016. I.J. acknowledges travel/accommodation expenses from MSD. F.D. has had a consulting role for Novartis and travel/accommodation expenses from Novartis. M.C. has had a consulting role for Novartis, Boehringer and Roche. D.H. has had a consulting role for Roche, Astra Zeneca, Boehringer, GSK and Thrombogenics, received honoraria from Roche, Astra Zeneca and Boehringer, and travel/accommodation expenses from Roche, Astra Zeneca, Boehringer, GSK, Thrombogenics and Merck. L.V.M. has had a consulting role for Astra Zeneca, GSK, Novartis and Eli Lilly. A.D.J.P. has received honoraria from Astra Zeneca, Boehringer and Novartis. L.Mo. has had a consulting role for Novartis, Astra Zeneca and Roche. All other authors declare no conflicts of interest to disclose.